Abstract

BackgroundAlthough routine vaccination of females before sexual debut against human papillomavirus (HPV) has been found to be cost-effective around the world, its cost-benefit has rarely been examined. We evaluate both the cost-effectiveness and cost-benefit of routine female adolescent nonavalent HPV vaccination in Hong Kong to guide its policy, and by extension that of mainland China, on HPV vaccination. One major obstacle is the lack of data on assortativity of sexual mixing. Such difficulty could be overcome by inferring sexual mixing parameters from HPV epidemiologic data.MethodsWe use an age-structured transmission model coupled with stochastic individual-based simulations to estimate the health and economic impact of routine nonavalent HPV vaccination for girls at age 12 on cervical cancer burden and consider vaccine uptake at 25%, 50%, and 75% with at least 20 years of vaccine protection. Bayesian inference was employed to parameterize the model using local data on HPV prevalence and cervical cancer incidence. We use the human capital approach in the cost-benefit analysis (CBA) and GDP per capita as the indicative willingness-to-pay threshold in the cost-effectiveness analysis (CEA). Finally, we estimate the threshold vaccine cost (TVC), which is the maximum cost for fully vaccinating one girl at which routine female adolescent nonavalent HPV vaccination is cost-beneficial or cost-effective.ResultsAs vaccine uptake increased, TVC decreased (i.e., economically more stringent) in the CBA but increased in the CEA. When vaccine uptake was 75% and the vaccine provided only 20 years of protection, the TVC was US$444 ($373–506) and $689 ($646–734) in the CBA and CEA, respectively, increasing by approximately 2–4% if vaccine protection was assumed lifelong. TVC is likely to be far higher when non-cervical diseases are included. The inferred sexual mixing parameters suggest that sexual mixing in Hong Kong is highly assortative by both age and sexual activity level.ConclusionsRoutine HPV vaccination of 12-year-old females is highly likely to be cost-beneficial and cost-effective in Hong Kong. Inference of sexual mixing parameters from epidemiologic data of prevalent sexually transmitted diseases (i.e., HPV, chlamydia, etc.) is a potentially fruitful but largely untapped methodology for understanding sexual behaviors in the population.

Highlights

  • Routine vaccination of females before sexual debut against human papillomavirus (HPV) has been found to be cost-effective around the world, its cost-benefit has rarely been examined

  • Very few studies have examined the corresponding cost-benefit, which is an important alternative criterion for health technology assessment because (1) in some jurisdictions, such as Hong Kong, health policymaking is based on cost-benefit instead of cost-effectiveness; (2) economists have suggested that cost-benefit analysis (CBA) is able to capture a wider range of the benefits of vaccination compared to cost-effectiveness analysis (CEA) [2]; and (3) CBA and CEA may lead to discordant conclusions regarding the economic favorability of health interventions due to different but sound methodologies and assumptions [3]

  • The primary objective of this study is to provide a robust evidence base for HPV vaccination policy in the sentinel Chinese population of Hong Kong by performing both CBA and CEA of routine female adolescent nonavalent HPV vaccination for reducing cervical cancer burden using methodology that conforms with health technology assessments in this city

Read more

Summary

Introduction

Routine vaccination of females before sexual debut against human papillomavirus (HPV) has been found to be cost-effective around the world, its cost-benefit has rarely been examined We evaluate both the costeffectiveness and cost-benefit of routine female adolescent nonavalent HPV vaccination in Hong Kong to guide its policy, and by extension that of mainland China, on HPV vaccination. The cost-effectiveness of routine female adolescent human papillomavirus (HPV) vaccination and other strategies (e.g., vaccinating males as well) has been extensively studied for many high-income countries (e.g., the UK, Australia, Canada) as well as middle- and low-income countries (e.g., Malaysia, Brazil, Peru) [1]. The health technology assessments framework for HPV vaccination in Hong Kong can serve as a reference for mainland China’s public health policy on prevention of cervical cancer, which is the second-most common cancer in women aged below 45 in the country [5]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call